Author: admin

DelveInsight’s “Uveitis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of uveitis, historical and forecasted epidemiology, as well as the uveitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Uveitis Market Forecast @ https://www.delveinsight.com/sample-request/uveitis-market

Key Takeaways from the Uveitis Market Report

• As per DelveInsight analysis, in 2022, there were approximately 1,009,025 Uveitis diagnosed prevalent cases in the 7MM.
• The total number of Uveitis diagnosed prevalent cases in the US was around 378,281 in 2022.
• The US contributed to the largest Uveitis diagnosed prevalent population, acquiring ~37.5% of the 7MM in 2022. Whereas Spain accounted for the least, with around ~7% of the total population share, respectively, in 2022.
• In the US, patients diagnosed with noninfectious uveitis (NIU) are higher in number than infectious uveitis (IU). In 2022, there were nearly 344,587 cases of NIU, while IU accounted for around 33,695 cases. These numbers are expected to rise during the forecast period due to the rise of overall uveitis infection in the US.
• According to DelveInsight estimates, in EU4 and the UK, based on anatomical location highest cases of uveitis were diagnosed in anterior uveitis, while intermediate uveitis has the least cases. In EU4 and the UK, anterior uveitis accounted for approximately 203,439, followed by 84,154 cases in posterior uveitis, 81,773 cases in pan uveitis, and 46,485 in intermediate uveitis in 2022, which are projected to increase during the forecast period.
• Japan accounted for approximately 214,892 diagnosed prevalent cases of uveitis, out of which nearly 8,039 cases were of HLA-B27-associated uveitis, 17,315 sarcoidosis, 9,894 Behçet’s disease, 8,658 Vogt–Koyanagi–Harada disease, 618 JIA, 309 ankylosing spondylitis, 3,092 tuberculosis, 11,749 herpes, 81,628 idiopathic, and 73,589 others cases in 2022. These uveitis cases are expected to change during the forecast period in Japan (2023–2034).
• The leading Uveitis Companies such as Tarsier Pharma, Oculis Pharma, Roche, Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin, Affibody Medical, Priovant Therapeutics, and others.
• Promising Uveitis Therapies such as Brepocitinib 45 mg PO QD, Izokibep, QLETLI, Baricitinib, Adalimumab, and others.

Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Uveitis Market Forecast @ Uveitis Treatment Market

Uveitis Epidemiology Segmentation in the 7MM

• Total Diagnosed Prevalent Cases
• Type-specific Diagnosed Prevalent Cases
• Diagnosed Prevalent Cases of Uveitis by Anatomical
• Etiology-specific Diagnosed Prevalent Cases

Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Uveitis Market Forecast @ Uveitis Prevalence

Uveitis Marketed Drugs

• XIPERE: Clearside Biomedical/Bausch+Lomb

XIPERE, a triamcinolone acetonide injectable suspension, is the first approved medicine delivery via injection for suprachoroidal use to treat macular edema associated with uveitis in the US. Delivering the medicine to the suprachoroidal space (SCS) allows targeted delivery of the therapy with low levels elsewhere in the eye.

• YUTIQ/ILUVIEN: EyePoint Pharmaceuticals/Alimera Sciences

YUTIQ is a sterile nonbioerodible intravitreal implant with 0.18 mg fluocinolone acetonide. It releases the drug at an initial rate of 0.25 µg/day in a 36-month sustained-release drug delivery system. YUTIQ contains a corticosteroid and is indicated for treating chronic noninfectious uveitis affecting the posterior segment of the eye. It is preloaded into a single-dose applicator to facilitate the injection of the implant directly into the vitreous. It was approved by the US FDA in October 2018 and launched commercially in February 2019.

Uveitis Emerging Drugs

• TRS01: Tarsier Pharma

TRS01, a lead product of Tarsier Pharmaceuticals, first in first-in-class topical immune modulator agent. Dazdotuftide (TRS) is a breakthrough platform technology for treating blinding ocular diseases. TRS was developed to ‘re-engineer’ the immune system. The platform approaches inflammatory diseases from within the system. The technology can effectively treat various autoimmune and inflammatory ocular diseases. TRS01 is a polypeptide conjugate with a dual mechanism of action; the investigational agent induces anti-inflammatory macrophages and inhibits the nuclear factor-kB (Nf-kB) signaling pathway by toll-like receptor 4 (TLR4).

• OCS-02 (licaminlimab): Oculis Pharma

OCS-02 (licaminlimab) is a single-chain antibody fragment (scFv) that binds to and neutralizes the activity of human TNFa, with a dual mechanism of action (MoA), anti-inflammation, and anti-necrosis. Unlike full-length monoclonal antibodies, scFv fragments can penetrate ocular surface tissues when used as eye drops due to the smaller molecule size giving it the potential to become the first approved topical biologic for DED (dry eye disease) (OCS-02 was previously known as LME636).

Discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Uveitis Market Forecast @ Uveitis Market Drivers and Barriers

Uveitis Drugs Market Insights

A severe intraocular inflammatory condition of the uveal tract known as uveitis frequently results in vision loss, blindness, and reduced quality of life. With the disease having a variable presentation, diagnosis and management are difficult. Treatment aims at obtaining quiescence of the disease, either by treating the infectious agent or treating the immune condition. The current promising pharmacological classes for uveitis treatment include corticosteroids, immunosuppressants, and biologics. The uveitis drugs market is growing, driven by innovative therapies and increasing global prevalence.

Uveitis Therapies and Companies

• TRS01: Tarsier Pharma
• Licaminlimab (OCS-02): Oculis Pharma
• Vamikibart (RO720220/RG6179): Roche/Eleven Biotherapeutics
• OLUMIANT (baricitinib): Eli Lilly and Company
• EYS606: Eyevensys
• Izokibep: Acelyrin/Affibody Medical
• Brepocitinib: Priovant Therapeutics (Roivant Sciences and Pfizer)

Uveitis Market Outlook

Uveitis is a serious intraocular inflammatory disorder of the uveal tract, often associated with visual impairment, blindness, and decreased quality of life. It often affects patients in their most active and economically productive years. It is the leading cause of preventable blindness worldwide and is a critically underserved disease in terms of treatment. With the disease having a variable presentation, diagnosis and management are difficult. A prompt diagnosis, with the correct diagnostic approach and assessment of appropriate treatment, is extremely important to reduce inflammation and attain complete remission, thereby mitigating or avoiding ocular complications, permanent cumulative damage, and long-term vision loss. Treatment aims at obtaining quiescence of the disease, either by treating the infectious agent or treating the immune condition.

Explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Uveitis Market Forecast @ Uveitis Clinical Trials Assessment

Scope of the Uveitis Market Report

• Coverage- 7MM
• Uveitis Companies- Tarsier Pharma, Oculis Pharma, Roche, Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin, Affibody Medical, Priovant Therapeutics, and others.
• Uveitis Therapies- Brepocitinib 45 mg PO QD, Izokibep, QLETLI, Baricitinib, Adalimumab, and others.
• Uveitis Market Dynamics: Uveitis Market Drivers and Uveitis Market Barriers
• Uveitis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Uveitis Unmet Needs, KOL’s views, Analyst’s views, Uveitis Market Access and Reimbursement

Table of Contents

1. Key Insights

2. Report Introduction

3. Uveitis Market Overview at a Glance

4. Methodology of Uveitis Epidemiology and Market

5. Executive Summary of Uveitis

6. Key Events

7. Disease Background and Overview of Uveitis

8. Patient Journey

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Uveitis: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/uveitis-market
Country: United States
Website: https://www.delveinsight.com/report-store/uveitis-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Uveitis Therapeutics Market Size in the 7MM was ~USD 1,468.66 million in 2022 and It is expected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Acute Myeloid Leukemia Pipeline Insights 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Acute Myeloid Leukemia Treatment Landscape @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight

Key Takeaways from the Acute Myeloid Leukemia Pipeline Report

• On May 20, 2026- Syndax Pharmaceuticals initiated a phase 3 study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
• On May 20, 2026- M.D. Anderson Cancer Center conducted a phase I-II clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML) or those with a mixed phenotype acute leukemia with a myeloid phenotype (MPAL).
• On May 12, 2026- AbbVie initiated a phase 4 study will assess the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) being treated with of the combination of azacitidine and venetoclax, in India.
• On May 08, 2026- Janssen Research & Development LLC conducted a study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.
• DelveInsight’s Acute Myeloid Leukemia Pipeline analysis depicts a robust space with 100+ active players working to develop 110+ pipeline treatment therapies.
• The leading Acute Myeloid Leukemia Companies such as Johnson & Johnson, Orca Biosystems, Inc., Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., Sunshine Lake Pharma, Sichuan Baili Pharmaceutical, Stemline Therapeutics, OncoVerity, Changzhou Qianhong Bio-pharma Co., Ltd., Delta-Fly Pharma, Menarini, Debiopharm International SA, Akeso Biopharma, AstraZeneca, Miltenyi Biomedicine GmbH, AB Science, Chordia Therapeutics, Molecular Partners AG, Takeda, ARCE Therapeutics, Galecto Biotech AB, Shenzhen TargetRx Co., Ltd., CRISPR Therapeutics, Lomond Therapeutics, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals and others.
• Promising Acute Myeloid Leukemia Therapies such as OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.

Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Acute Myeloid Leukemia Clinical Trials Assessment

The Acute Myeloid Leukemia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Acute Myeloid Leukemia Pipeline Report also highlights the unmet needs with respect to the Acute Myeloid Leukemia.

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) is a rapidly progressing myeloid neoplasm characterized by the clonal expansion of immature myeloid-derived cells, known as blasts, in the peripheral blood and bone marrow. This expansion results in ineffective erythropoiesis and megakaryopoiesis, clinically manifesting as relatively rapid bone marrow failure compared to chronic and indolent leukemias. This leads to inadequate production of red blood cells and platelets.

Acute Myeloid Leukaemia Emerging Drugs Profile

• Orca-T: Orca Biosystems, Inc.

Orca-T is an investigational allogeneic T-cell immunotherapy under evaluation for the treatment of multiple hematologic malignancies including acute leukemias and myelodysplastic syndromes. Orca-T is composed of highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from either related or unrelated matched donors. Currently, the drug is being evaluated in the Preregistration stage of its development for the treatment of Acute Myeloid Leukemia.

• Bleximenib: Johnson & Johnson

Bleximenib (JNJ-75276617) is an investigational, oral, small-molecule menin-KMT2A inhibitor showing promising activity against acute myeloid leukemia (AML) with KMT2A rearrangements or NPM1 mutations. It targets a key oncogenic interaction between menin and KMT2A fusion proteins, disrupting a pathway that drives leukemic cell growth in patients with KMT2Ar or NPM1m mutations. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Acute Myeloid Leukemia.

• Romaciclib: Ryvu Therapeutics

Romaciclib is a highly selective inhibitor of CDK8 and CDK19, minimizing off-target effects and enhancing therapeutic efficacy. This targeted approach disrupts key transcriptional programs essential for cancer cell survival while sparing healthy cells. Romaciclib has demonstrated a low potential for drug-drug interactions, making it a safer choice for patients undergoing multiple concurrent treatments. This reduces the likelihood of adverse interactions and supports better overall treatment outcomes. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Acute Myeloid Leukemia.

• ABD-3001: Advanced BioDesign

ABD-3001, is a small-molecules inhibitor of the ALDH family of enzymes that is at the initial stage of clinical development for a wide range of cancers, including acute myeloid leukemia. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Acute Myeloid Leukemia. This drug irreversibly binds to and inhibits ALDH1 and ALDH3, leading to metabolic stress and destruction of cancer stem cells. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Acute Myeloid Leukemia.

• CER-1236: CERo Therapeutics Holdings, Inc.

CER-1236 is an autologous chimeric engulfment receptor T cell (CER-T) which fuses external domain of TIM-4 with intracellular domains from T cells and innate immune cells including Toll-like receptor 2 (TLR2), CD28 and CD3ζ. This receptor binds TIM-4-ligand (phosphatidylserine) on tumor cells leading to phagocytosis and lysis of target cells followed by tumor antigen processing and cross-presentation to induce an adaptive immune response. CER-1236 was shown to eliminate AML cell in vitro, and in vivo in a xenograft model. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Acute Myeloid Leukemia.

• PRO CAR-301: Promicell INC.

PRO CAR-301 is an autologous CD33-directed CAR T cell that integrates a next-generation armor known as “SAVVY/IL-18”. It is an armored CD33-specific CAR T therapy for acute myeloid leukemia. It targets CD33, a cell surface protein expressed by mature myeloid cells and hematopoietic stems cells. This protein is expressed on over 80% of AML cells and hematopoietic stem cells which makes it an effective treatment target. Currently, the drug is being evaluated in the preclinical stage of its development for the treatment of Acute Myeloid Leukemia.

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Acute Myeloid Leukemia Unmet Needs

The Acute Myeloid Leukemia pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Myeloid Leukemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukemia Treatment.
• Acute Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Myeloid Leukemia market

Acute Myeloid Leukemia Companies

Johnson & Johnson, Orca Biosystems, Inc., Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., Sunshine Lake Pharma, Sichuan Baili Pharmaceutical, Stemline Therapeutics, OncoVerity, Changzhou Qianhong Bio-pharma Co., Ltd., Delta-Fly Pharma, Menarini, Debiopharm International SA, Akeso Biopharma, AstraZeneca, Miltenyi Biomedicine GmbH, AB Science, Chordia Therapeutics, Molecular Partners AG, Takeda, ARCE Therapeutics, Galecto Biotech AB, Shenzhen TargetRx Co., Ltd., CRISPR Therapeutics, Lomond Therapeutics, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals and others.

The Acute Myeloid Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acute Myeloid Leukaemia Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

See the latest progress in drug development and clinical research @ Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives

Scope of the Acute Myeloid Leukemia Pipeline Report

• Coverage- Global
• Acute Myeloid Leukemia Companies- Johnson & Johnson, Orca Biosystems, Inc., Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., Sunshine Lake Pharma, Sichuan Baili Pharmaceutical, Stemline Therapeutics, OncoVerity, Changzhou Qianhong Bio-pharma Co., Ltd., Delta-Fly Pharma, Menarini, Debiopharm International SA, Akeso Biopharma, AstraZeneca, Miltenyi Biomedicine GmbH, AB Science, Chordia Therapeutics, Molecular Partners AG, Takeda, ARCE Therapeutics, Galecto Biotech AB, Shenzhen TargetRx Co., Ltd., CRISPR Therapeutics, Lomond Therapeutics, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals and others.
• Acute Myeloid Leukemia Therapies- OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.
• Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Acute Myeloid Leukemia Pipeline Analysis Today! @ Acute Myeloid Leukemia Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Acute Myeloid Leukemia (AML): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Myeloid Leukemia (AML) – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Orca-T: Orca Biosystems, Inc.
9. Mid Stage Products (Phase II)
10. Romaciclib: Ryvu Therapeutics
11. Early Stage Products (Phase I)
12. CER-1236: CERo Therapeutics Holdings, Inc.
13. Preclinical and Discovery Stage Products
14. PRO CAR-301: Promicell Inc.
15. Inactive Products
16. Acute Myeloid Leukemia (AML) Key Companies
17. Acute Myeloid Leukemia (AML) Key Products
18. Acute Myeloid Leukemia (AML) – Unmet Needs
19. Acute Myeloid Leukemia (AML) – Market Drivers and Barriers
20. Acute Myeloid Leukemia (AML) – Future Perspectives and Conclusion
21. Acute Myeloid Leukemia (AML) Analyst Views
22. Acute Myeloid Leukemia (AML) Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Myeloid Leukemia Pipeline Shows Potential with Active Contributions from 100+ Key Companies | DelveInsight

DelveInsight’s “Renal Cell Carcinoma Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Renal Cell Carcinoma Treatment Landscape @ Renal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Renal Cell Carcinoma Pipeline Report

• On May 29, 2026- Merck Sharp & Dohme LLC announced a phase 3 study is to learn if people who receive belzutifan and zanzalintinib live longer. A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
• On May 22, 2026- Oncorena AB initiated a phase I/II study evaluating the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal carcinoma. The study will include up to 75 patients and is conducted in 3 parts. The study will consist of 3 parts: Part A – an intra-patient dose escalation part, followed by a dose exposure (Part B), followed by a dose expansion (Part C).
• On May 22, 2026- Pfizer conducted a phase 1B/2 study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them
• On May 20, 2026- M.D. Anderson Cancer Center conducted a Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
• DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Renal Cell Carcinoma treatment.
• The leading Renal Cell Carcinoma Companies such as Telix Pharmaceuticals (Innovations) Pty Limited, Arcus Biosciences, Inc., Zhejiang Haichang Biotech Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Consorzio Oncotech, Beijing Biotech, Imbioray (Hangzhou) Biomedicine Co., Ltd., Oncorena AB, UTC Therapeutics Inc., Bristol-Myers Squibb, HiberCell, Inc., Xencor, Inc., Neomorph, Inc., Arcus Biosciences, Inc., Grit Biotechnology and others.
• Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.

Gain in-depth knowledge of key Renal Cell Carcinoma clinical trials, emerging drugs @ Renal Cell Carcinoma Clinical Trials Assessment

The Renal Cell Carcinoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Renal Cell Carcinoma Pipeline Report also highlights the unmet needs with respect to the Renal Cell Carcinoma.

Renal Cell Carcinoma Overview

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, originating from the lining of the renal tubules in the kidney. It accounts for approximately 85–90% of all kidney cancers. RCC often develops silently in the early stages, and many cases are discovered incidentally during imaging studies performed for other conditions. Common symptoms in advanced disease may include hematuria, flank pain, weight loss, fatigue, and a palpable abdominal mass. Several histological subtypes exist, with clear cell renal cell carcinoma being the most common.

Renal Cell Carcinoma Emerging Drugs Profile

• Casdatifan: Arcus Biosciences

Casdatifan (AB521) is an investigational oral small-molecule hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor being developed for clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. HIF-2α acts as a “master switch” that activates multiple genes under low-oxygen conditions, and in most patients with ccRCC this pathway remains abnormally activated because of VHL pathway abnormalities, promoting tumor growth and survival. Casdatifan is designed to provide deep and durable inhibition of the HIF-2α pathway, thereby blocking tumor proliferation, angiogenesis, treatment resistance, and cancer cell survival. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Renal Cell Carcinoma.

• BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.

BL-B01D1 is a first-in-class EGFR × HER3 bispecific antibody-drug conjugate (ADC) developed for the treatment of advanced solid tumors, including renal cell carcinoma and other urinary system tumors. The drug is designed to simultaneously target epidermal growth factor receptor (EGFR) and HER3 expressed on tumor cells and deliver a topoisomerase I inhibitor payload directly into cancer cells, thereby promoting selective tumor cell killing while limiting systemic toxicity. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Renal Cell Carcinoma.

• Orellanine: Oncorena AB

Orellanine is a first-in-class investigational therapy being developed for metastatic renal cell carcinoma, particularly clear-cell and papillary renal cell carcinoma. Orellanine is a toxin originally derived from mushrooms of the Cortinarius family and is being developed as an organ-specific chemotherapy for kidney cancer. The mechanism of action involves selective uptake into renal cancer cells through transporters highly expressed on kidney tumor cells, where it induces oxidative stress, disrupts mitochondrial function, down-regulates intracellular defense mechanisms, and ultimately triggers apoptosis and tumor cell death. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Renal Cell Carcinoma.

• XmAb819: Xencor, Inc.

XmAb819 is a first-in-class, tumor-targeted XmAb® 2+1 bispecific antibody being developed for patients with advanced clear cell renal cell carcinoma (ccRCC). The drug is designed to target ENPP3, an antigen highly expressed on kidney cancer cells, while simultaneously engaging CD3 on T cells to activate targeted immune-mediated killing of tumor cells. According to the company, the XmAb 2+1 format contains two ENPP3 binding domains and one CD3 binding domain, enabling selective binding to tumor cells with high antigen density while potentially sparing normal tissues. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Renal Cell Carcinoma.

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Renal Cell Carcinoma Unmet Needs

The Renal Cell Carcinoma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Renal Cell Carcinoma Treatment.
• Renal Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Renal Cell Carcinoma market.

Renal Cell Carcinoma Companies

Telix Pharmaceuticals (Innovations) Pty Limited, Arcus Biosciences, Inc., Zhejiang Haichang Biotech Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Consorzio Oncotech, Beijing Biotech, Imbioray (Hangzhou) Biomedicine Co., Ltd., Oncorena AB, UTC Therapeutics Inc., Bristol-Myers Squibb, HiberCell, Inc., Xencor, Inc., Neomorph, Inc., Arcus Biosciences, Inc., Grit Biotechnology and others

Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Renal Cell Carcinoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Transform your understanding of the Renal Cell Carcinoma Pipeline! @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Renal Cell Carcinoma Pipeline Report

• Coverage- Global
• Renal Cell Carcinoma Companies- Telix Pharmaceuticals (Innovations) Pty Limited, Arcus Biosciences, Inc., Zhejiang Haichang Biotech Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Consorzio Oncotech, Beijing Biotech, Imbioray (Hangzhou) Biomedicine Co., Ltd., Oncorena AB, UTC Therapeutics Inc., Bristol-Myers Squibb, HiberCell, Inc., Xencor, Inc., Neomorph, Inc., Arcus Biosciences, Inc., Grit Biotechnology and others.
• Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
• Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Renal Cell Carcinoma Pipeline Analysis Today! @ Renal Cell Carcinoma Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Renal Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Renal Cell Carcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Casdatifan: Arcus Biosciences
9. Mid Stage Products (Phase II)
10. BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.
11. Early Stage Products (Phase I)
12. XmAb819: Xencor, Inc.
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Renal Cell Carcinoma Key Companies
16. Renal Cell Carcinoma Key Products
17. Renal Cell Carcinoma – Unmet Needs
18. Renal Cell Carcinoma – Market Drivers and Barriers
19. Renal Cell Carcinoma – Future Perspectives and Conclusion
20. Renal Cell Carcinoma Analyst Views
21. Renal Cell Carcinoma Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Renal Cell Carcinoma Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Gorlin Syndrome Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gorlin Syndrome pipeline landscape. It covers the Gorlin Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gorlin Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Gorlin Syndrome Treatment Drugs @ https://www.delveinsight.com/sample-request/gorlin-syndrome-pipeline-insight

Key Takeaways from the Gorlin Syndrome Pipeline Report

• On May 18, 2026, Cureus Researchers – A new case report titled “Extensive Flexural Basal Cell Carcinomas Revealing Gorlin-Goltz Syndrome with Marked Histopathologic Diversity” was published, highlighting the clinical complexity and diagnostic challenges associated with Gorlin Syndrome and emphasizing the need for early recognition and multidisciplinary management.
• In January 2026- Nathalie Zeitouni initiated a study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions.DelveInsight’s Gorlin Syndrome Pipeline analysis depicts a robust space with 5+ Gorlin Syndrome companies working to develop 5+ pipeline treatment therapies.
• DelveInsight’s Gorlin Syndrome Pipeline analysis depicts a robust space with 5+ Gorlin Syndrome companies working to develop 5+ pipeline treatment therapies.
• The leading Gorlin Syndrome Companies such as Palvella Therapeutics Inc., PellePharm, Ascend Biopharmaceuticals and others.
• Promising Gorlin Syndrome Pipeline Therapies such as Patidegib Topical Gel, Vismodegib, PTX-022, GDC-0449, LDE225, ASN-002, LDE225 0.25% and others.

Find out more about Gorlin Syndrome Therapeutics Assessment @ Gorlin Syndrome Preclinical and Discovery Stage Products

The Gorlin Syndrome Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Gorlin Syndrome Pipeline Report also highlights the unmet needs with respect to the Gorlin Syndrome.

Gorlin Syndrome Overview

A rare, inherited disorder that affects many organs and tissues in the body. People with this disorder have a very high risk of developing basal cell skin cancer during adolescence or early adulthood. They are also at risk of developing medulloblastoma (a type of brain cancer) and other types of cancer. Gorlin syndrome may also cause benign (not cancer) tumors in the jaw, heart, or ovaries. Other signs and symptoms include a large head and unusual facial features; small pits in the skin on the hands and feet; abnormalities of the spine, ribs, or skull; eye problems; and developmental problems. Gorlin syndrome is caused by a mutation (change) in the PTCH1 gene. Also called basal cell nevus syndrome, BCNS, NBCCS, and nevoid basal cell carcinoma syndrome.

Gorlin Syndrome Emerging Drugs

• PTX-022: Palvella Therapeutics

PTX-022 is a novel formulation of rapamycin which leverages Palvella’s QTORIN technology. QTORIN is a proprietary and patent-pending technology that employs a specific composition of excipients that enable distribution of rapamycin into the basal keratinocytes which harbor the mutant keratin genes that are the primary defect in pachyonychia congenita. In addition to PC, QTORIN and its related technologies are being investigated in other serious, rare genodermatoses, including Gorlin Syndrome.

Explore the dynamic world of drug development with our latest Gorlin Syndrome Pipeline Insights report! Don’t miss this opportunity to stay informed—download now! @ Gorlin Syndrome Treatment Drugs

The Gorlin Syndrome pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Gorlin Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gorlin Syndrome Treatment.
• Gorlin Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gorlin Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gorlin Syndrome market.

Gorlin Syndrome Companies

Palvella Therapeutics Inc., PellePharm, Ascend Biopharmaceuticals and others.

Gorlin Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Gorlin Syndrome Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Gorlin Syndrome Pipeline Therapies @ Gorlin Syndrome Clinical Trials Assessment

Scope of the Gorlin Syndrome Pipeline Report

• Coverage- Global
• Gorlin Syndrome Companies-Palvella Therapeutics Inc., PellePharm, Ascend Biopharmaceuticals and others.
• Gorlin Syndrome Pipeline Therapies- Patidegib Topical Gel, Vismodegib, PTX-022, GDC-0449, LDE225, ASN-002, LDE225 0.25% and others.
• Gorlin Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gorlin Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which Gorlin Syndrome Companies are leading the way in drug discovery? Download now to stay at the forefront of pharmaceutical innovation!” @ Gorlin Syndrome Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Gorlin-syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutics Assessment
6. Gorlin-syndrome– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. PTX-022: Palvella Therapeutics
10. Early Stage Products (Phase I)
11. Discovery Stage Products
12. Inactive Products
13. Gorlin-syndrome Key Companies
14. Gorlin-syndrome Key Products
15. Gorlin-syndrome- Unmet Needs
16. Gorlin-syndrome- Market Drivers and Barriers
17. Gorlin-syndrome- Future Perspectives and Conclusion
18. Gorlin-syndrome Analyst Views
19. Gorlin-syndrome Key Companies
20. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/gorlin-syndrome-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/gorlin-syndrome-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gorlin Syndrome Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Schizophrenia Pipeline Insight 2026” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in the Schizophrenia pipeline landscape. It covers the Schizophrenia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Schizophrenia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Schizophrenia Pipeline? @ https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight

Key Takeaways from the Schizophrenia Pipeline Report

• On June 02, 2026- Bristol-Myers Squibb initiated a phase 3 study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
• On May 28, 2026- Otsuka Pharmaceutical Development & Commercialization Inc. conducted a study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 13 years old -65 years old who have been diagnosed with schizophrenia.
• On May 26, 2026- Neurocrine Biosciences announced a phase 2a study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
• On May 22, 2026- Eli Lilly and Company conducted a phase 2 study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment period will last a maximum of 12 months, and the follow up period will last approximately 2 months. The length of time of your study participation may last up to approximately 15 months.
• DelveInsight’s Schizophrenia Pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Schizophrenia treatment.
• The leading Schizophrenia Companies such as Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals, and others.
• Promising Schizophrenia Therapies such as Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.

Want to know which companies are leading innovation in Schizophrenia? @ Schizophrenia Clinical Trials Assessment

The Schizophrenia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Schizophrenia Pipeline Report also highlights the unmet needs with respect to the Schizophrenia.

Schizophrenia Overview

Schizophrenia is a chronic, severe mental disorder that affects how a person thinks, feels, and behaves. It is characterized by episodes of psychosis, which involve disturbances in thought processes, perceptions, emotional responsiveness, and social interactions. Schizophrenia affects about 1% of the population worldwide and typically manifests in late adolescence or early adulthood. The exact cause of schizophrenia is not fully understood, but it is believed to result from a complex interplay of genetic, environmental, and neurobiological factors.

Schizophrenia Emerging Drugs Profile

• Ulotaront: Sunovion Pharmaceuticals

SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity that is under investigation for the treatment of schizophrenia and other psychiatric conditions. Sunovion discovered SEP-363856 in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Currently, the drug is in the Phase III stage of its development for the treatment of Schizophrenia

• Emraclidine: Abbvie

Emraclidine is a selective M4 receptor PAM, meaning it selectively targets the M4 receptor to harness the anti-psychotic effect believed to be associated with this receptor while minimizing the side effects associated with other pan-muscarinic agonists. The company believes emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development. Currently, the drug is in the Phase II stage of its development for the treatment of Schizophrenia.

• CY 6463: Cyclerion Therapeutics

CY6463 is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that precisely controls key aspects of physiology throughout the body. As an sGC stimulator, CY6463 acts as a positive allosteric modulator to sensitize the sGC enzyme to NO, increase the production of cGMP, and thereby amplify endogenous NO signaling. By compensating for deficient NO-sGC-cGMP signaling, CY6463 and other sGC stimulators may have broad therapeutic potential as a treatment to improve cognition and function in people with serious CNS diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Schizophrenia.

If you’re tracking ongoing Schizophrenia Clinical trials, this press release is a must-read @ Schizophrenia Treatment Drugs

The Schizophrenia Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Schizophrenia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Schizophrenia Treatment.
• Schizophrenia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Schizophrenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Schizophrenia market.

Schizophrenia Companies

Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.

Schizophrenia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Schizophrenia Products have been categorized under various Molecule types such as,

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Schizophrenia Pipeline Report covers it all @ Schizophrenia Market Drivers and Barriers, and Future Perspectives

Scope of the Schizophrenia Pipeline Report

• Coverage- Global
• Schizophrenia Companies- Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
• Schizophrenia Therapies- Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.
• Schizophrenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Schizophrenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Schizophrenia Treatment landscape in this detailed analysis @ Schizophrenia Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Schizophrenia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Schizophrenia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ulotaront: Sunovion Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Emraclidine: AbbVie
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CY 6463: Cyclerion Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Schizophrenia Key Companies
21. Schizophrenia Key Products
22. Schizophrenia- Unmet Needs
23. Schizophrenia- Market Drivers and Barriers
24. Schizophrenia- Future Perspectives and Conclusion
25. Schizophrenia Analyst Views
26. Schizophrenia Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schizophrenia Pipeline Accelerates as 55+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight